Understanding how EGFR-mutant lung cancer changes and becomes resistant to treatment
Drivers of histologic transformation in EGFR-mutant lung cancer
This study is looking at how lung cancers with EGFR mutations start off responding well to treatment but then change and become resistant, and it aims to find out what causes these changes by examining tumor samples from patients, which could help develop better ways to keep the cancer from transforming.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10892116 on NIH RePORTER |
What this research studies
This research investigates how EGFR-mutant lung cancers initially respond to treatment but later develop resistance, particularly through changes in their cellular structure. By examining tumors from patients that have transformed into different types of lung cancer, the study aims to identify the molecular factors that drive these changes. The researchers will analyze both pre- and post-transformation tumor samples to understand the mechanisms behind this lineage plasticity. This knowledge could lead to new strategies to prevent or counteract the transformation of cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with EGFR-mutant lung adenocarcinoma who are experiencing or at high risk for transformation to small cell or squamous cell lung cancer.
Not a fit: Patients with lung cancer that does not have EGFR mutations or those who are not at risk for lineage transformation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with EGFR-mutant lung cancer, potentially preventing the progression to more aggressive cancer forms.
How similar studies have performed: Other research has shown promising results in understanding cancer transformation, but this specific approach focusing on EGFR-mutant lung cancer is relatively novel.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Yu, Helena — Sloan-Kettering Inst Can Research
- Study coordinator: Yu, Helena
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.